Evidence map›Paper›PMID 42141518›Full record

ArticleProtein science : a publication of the Protein Society2026

Covalent drug rescue of multiple p53 mutants by stabilizing vinyl sulfone fragments hints to a specific refolding mechanism for R282W.

Jason Stahlecker, Theresa Klett, Robert Spiegel, Martin Schwer, Finn Mier, Sven Aldea, Benedikt Masberg, Michael Lämmerhofer, Thilo Stehle, Frank M Böckler

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jason StahleckerLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0000-0002-0044-4037
Theresa KlettLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0000-0003-4049-9363
Robert SpiegelLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0009-0002-5054-1131
Martin SchwerLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0009-0005-0202-5353
Finn MierLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0000-0003-3409-4626
Sven AldeaLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0009-0007-1144-0860
Benedikt MasbergInstitute of Pharmaceutical Sciences, Pharmaceutical (Bio-)Analysis, University of Tübingen, Tübingen, Germany.ORCID 0000-0003-2041-4983
Michael LämmerhoferInstitute of Pharmaceutical Sciences, Pharmaceutical (Bio-)Analysis, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-1318-0974
Thilo StehleInterfaculty Institute of Biochemistry, Eberhard Karls Universität Tübingen|, Tübingen, Germany.ORCID 0000-0002-4571-8548
Frank M BöcklerLab for Molecular Design & Pharm. Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.ORCID 0000-0001-8738-6716

Funding

Deutsche Forschungsgemeinschaft INST 37/935-1 FUGG (BinAC cluster)Deutsche Forschungsgemeinschaft INST 40/575-1 FUGG (JUSTUS 2 cluster)
6 · The paper itself

Abstract

The tumor suppressor protein p53 plays a crucial role in cell cycle regulation. In approximately 50% of all tumors, mutations in p53 are observed. Although the top hot spot mutations impair DNA binding, other mutations affect the thermal stability of the protein, leading to its rapid denaturation in physiological conditions. Previously, we have identified VS004, a vinyl sulfone containing fragment that stabilized p53C-WT by about 5°C. In this study, we screened the CovLib fragments VS002, VS003, VS004, and two VS004 analogs against wild-type p53C, as well as the mutants R273H, Y220C, and R282W. VS004 and its analogs demonstrated stabilizing effects on all tested p53 variants, with the strongest effect (almost 6°C) on R282W. We solved the crystal structures of VS004-2 bound to Y220C and R282W. In the Y220C crystal structure, VS004-2 bound to C277 and stabilized the loop L1. For R282W, we observed binding to C275, which leads to an unexpected structural reorganization of the C-terminal helix H2. Although the arylated cysteines are both near the DNA-binding interface, fluorescence polarization experiments using five different response elements confirm that DNA binding appears not to be compromised. The compounds present an interesting starting point for both general and mutant specific p53 stabilization.

Indexed as

Protein RefoldingSulfonesTumor Suppressor Protein p53Crystallography, X-RayHumansModels, MolecularMutationProtein Stabilitydivinyl sulfoneSulfonesTP53 protein, humanTumor Suppressor Protein p53cancercell cyclecovalent modificationstabilizationvinyl‐sulfone

Identifiers

PMID42141518
PMCPMC13179279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.